(+)-trans-3-Cyclohexyl proline | 462123-82-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+)-trans-3-Cyclohexyl proline
• 英文别名: (2S,3R)-3-cyclohexylpyrrolidine-2-carboxylic acid
• CAS: 462123-82-6
• 化学式: C₁₁H₁₉NO₂
• 分子量: 197.277
• InChiKey: FMXXVXZXZFKHRJ-ZJUUUORDSA-N

物化性质

• 沸点：
  343.9±35.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-trans-3-Cyclohexyl proline 在 palladium on activated charcoal 硫酸 、 氢气 、 sodium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 生成 (2S,3R)-3-Cyclohexyl-pyrrolidine-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants

  摘要：

  We recently described the identification of an optimized alpha-ketoamide warhead for our series of HCV NS3(.)4A inhibitors. We report herein a series of HCV protease inhibitors incorporating 3-alkyl-substituted prolines in P-2. These compounds show exceptional enzymatic and cellular potency given their relatively small size. The marked enhancement of activity of these 3-substituted proline derivatives relative to previously reported 4-hydroxyproline derivatives constitutes additional evidence for the importance of the S-2 binding pocket as the defining pharmacophore for inhibition of the NS3(.)4A enzyme. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.078
• 作为产物：
  描述：

  (2S,3R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-3-cyclohexyl-5-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 在 chromium(VI) oxide 、 dimethyl sulfide borane 、 硫酸 、 四丁基氟化铵 、 水 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 反应 30.75h， 生成 (+)-trans-3-Cyclohexyl proline
  参考文献：
  名称：

  Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors

  摘要：

  Several caspases have been implicated in the pathogenesis of Huntington's disease (HD); however, existing caspase inhibitors lack the selectivity required to investigate the specific involvement of individual caspases in the neuronal cell death associated with HD. In order to explore the potential role played by caspase-2, the potent but non-selective canonical Ac-VDVAD-CHO caspase-2 inhibitor 1 was rationally modified at the P-2 residue in an attempt to decrease its activity against caspase-3. With the aid of structural information on the caspase-2, and -3 active sites and molecular modeling, a 3-(S)-substituted-L-proline along with four additional scaffold variants were selected as P-2 elements for their predicted ability to clash sterically with a residue of the caspase-3 S-2 pocket. These elements were then incorporated by solid-phase synthesis into pentapeptide aldehydes 33a-v. Proline-based compound 33h bearing a bulky 3-(S)-substituent displayed advantageous characteristics in biochemical and cellular assays with 20- to 60-fold increased selectivity for caspase-2 and similar to 200-fold decreased caspase-3 potency compared to the reference inhibitor 1. Further optimization of this prototype compound may lead to the discovery of valuable pharmacological tools for the study of caspase-2 mediated cell death, particularly as it relates to HD. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.020

文献信息

• Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
  申请人：——

  公开号：US20040102478A1

  公开（公告）日：2004-05-27

  Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, rhinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  公式（I）的化合物是VLA-4和/或alpha4/beta7的拮抗剂，因此可用于抑制或预防细胞黏附和细胞黏附介导的病理过程。这些化合物可以制成药物组合物，并适用于治疗艾滋病相关痴呆症、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病，包括溃疡性结肠炎和克隆病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、鼻炎、类风湿性关节炎、败血性关节炎、中风、肿瘤转移、葡萄膜炎和1型糖尿病的治疗。
• Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
  申请人：Doherty George

  公开号：US06943180B2

  公开（公告）日：2005-09-13

  Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, rhinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  化学式为（I）的化合物是VLA-4和/或alpha4/beta7的拮抗剂，因此可用于抑制或预防细胞黏附和细胞黏附介导的病理过程。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆症、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病，包括溃疡性结肠炎和克罗恩病、炎症性肺疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、鼻炎、类风湿性关节炎、败血性关节炎、中风、肿瘤转移、葡萄膜炎和1型糖尿病的治疗。
• SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1389200A1

  公开（公告）日：2004-02-18
• EP1389200A4
  申请人：——

  公开号：EP1389200A4

  公开（公告）日：2007-03-28
• US6943180B2
  申请人：——

  公开号：US6943180B2

  公开（公告）日：2005-09-13